Transplantation: Rituximab induction for prevention of HLA-antibody rebound

Nature Reviews Nephrology

Volumn 10, Issue 12, 2014, Pages 682-683

  Sood, Puneet ^a   Hariharan, Sundaram ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DACLIZUMAB; DONOR SPECIFIC ANTIBODY; EPITOPE; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PANEL REACTIVE ANTIBODY; PROTEASOME INHIBITOR; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; HLA ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP INCOMPATIBILITY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPLEMENT DEPENDENT CYTOTOXICITY; FLOW CYTOMETRY; FOLLOW UP; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAINTENANCE THERAPY; MEMORY CELL; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PATIENT HISTORY OF TRANSPLANTATION; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC DESENSITIZATION; ADVERSE EFFECTS; CASE CONTROL STUDY; COMPARATIVE STUDY; DESENSITIZATION; DRUG EFFECTS; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; MALE; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CASE-CONTROL STUDIES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 84911981184     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.179     Document Type: Review

References (10)

1. Schold, J. D. et al. Comorbidity burden and perioperative complications for living kidney donors in the United States. Clin. J. Am. Soc. Nephrol. 8, 1773-1782 (2013).
2. Segev, D. L. et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 303, 959-966 (2010).
3. Montgomery, R. A. et al. Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med. 365, 318-326 (2011).
4. Lefaucheur, C. et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am. J. Transplant. 8, 324-331 (2008).
5. Lefaucheur, C. et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21, 1398-1406 (2010).
6. Jackson, A. M. et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int. http://dx.doi.org/10.1038/ki.2014.261.
7. Vo, A. A. et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359 242-251 (2008).
8. Jin, M. K. et al. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc. 44, 200-203 (2012).
9. Loupy, A. et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 89, 1403-1410 (2010).
10. Takagi, T., Ishida, H., Shirakawa, H., Shimizu, T. & Tanabe, K. Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transpl. Immunol. 23 220-223 (2010).